Ana Kusnetzow, Ph.D. serves as Vice President of Biology at Radionetics. She was most recently Senior Director at Crinetics Pharmaceuticals, Inc. where she led the in vitro pharmacology group that supported multiple discovery programs. She was also the program leader for a first-in-class ACTH antagonist, CRN04894, for the treatment of diseases caused by excess ACTH (e.g., Cushing’s disease and congenital adrenal hyperplasia) and co-led the Crinetics discovery program that gave rise to the nonpeptide targeted radiotherapeutics platform that is the basis of the Radionetics pipeline. As a founding member of Crinetics, she established diverse biology capabilities supporting small molecule and biologics drug development from the ground up, culminating in a $40 million Series A and was a significant contributor to the success of the discovery team that culminated in the nomination of several developmental candidates. Throughout her career and graduate and post-graduate work, Dr. Kusnetzow has focused on the structural and pharmacologic characterization of G-protein-coupled receptors to aid in drug discovery and development. Dr. Kusnetzow holds a Ph.D. in Chemistry from Syracuse University, as well as a B.S. from Adrian College. She also conducted post-graduate training at the Jules Stein Eye Institute, Geffen School of Medicine at the University of California, Los Angeles.